Zur Rose Group AG Stock
Price
Target price
€91.50
€91.50
-
-
-
-
14.07.23 / Tradegate
WKN: A0Q6J0 / Name: Zur Rose Group / Stock / ? /
We currently do not receive price updates for this security
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for Zur Rose Group
sharewise wants to provide you with the best news and tools for Zur Rose Group, so we directly link to the best financial data sources.
Financials
News
DocMorris announces the start of the tender offer period for its Outstanding Convertible Bonds due 2025
DocMorris announces the start of the tender offer period for its Outstanding Convertible Bonds due 2025
Resolutions of the 31st Annual General Meeting of DocMorris AG of 2 May 2024 in Zurich
Resolutions of the 31st Annual General Meeting of DocMorris AG of 2 May 2024 in Zurich
Final allocation of DocMorris CHF 200 million Convertible Bonds Offering
Final allocation of DocMorris CHF 200 million Convertible Bonds Offering
DocMorris successfully completes the placement of CHF 200 million Convertible Bonds due 2029
DocMorris successfully completes the placement of CHF 200 million Convertible Bonds due 2029
DocMorris launches approx. CHF 200 million Convertible Bonds due 2029
DocMorris launches approx. CHF 200 million Convertible Bonds due 2029
DocMorris continues to grow in the first quarter of 2024 and creates digital access to the entire e-prescription market
DocMorris continues to grow in the first quarter of 2024 and creates digital access to the entire e-prescription market
DocMorris AG: DocMorris receives gematik approval for simple digital e-prescription redemption via health card
DocMorris AG: DocMorris receives gematik approval for simple digital e-prescription redemption via health card
DocMorris AG: Significant earnings improvement in 2023; e-prescription is standard in Germany
DocMorris AG: Significant earnings improvement in 2023; e-prescription is standard in Germany
DocMorris achieves significant revenue growth in the fourth quarter of 2023 and confirms inflection point by increasing active customer base
DocMorris achieves significant revenue growth in the fourth quarter of 2023 and confirms inflection point by increasing active customer base
DocMorris optimises organisational structure and prepares for e-prescription growth in Germany
DocMorris optimises organisational structure and prepares for e-prescription growth in Germany